Comparison of US Cancer Center Recommendations for Prostate Cancer Screening With Evidence-Based Guidelines
Menée aux Etats-Unis, cette étude analyse la concordance entre les recommandations des centres anticancer sur le dépistage du cancer de la prostate par dosage du PSA et les recommandations nationales de bonnes pratiques
The US Preventive Services Task Force, American Cancer Society, and American Urological Association recommend that men at average risk engage in shared decision-making with their physicians regarding the decision to start prostate cancer screening with prostate-specific antigen (PSA) testing at age 50 or 55 years, and most recommend discontinuing screening at age 70 years or in men with fewer than 10 years of life expectancy. These recommendations reflect evidence that PSA screening has both benefits and harms. Screening may reduce the incidence of metastatic disease, and possibly prostate cancer–specific mortality, but there is no clear evidence that screening decreases all-cause mortality. Potential harms include false-positive results, psychological effects, biopsy complications, and treatment sequelae for overdiagnosed or indolent tumors.
JAMA Internal Medicine , résumé, 2021